Gilead Sciences GILD
-
Gilead Sciences ( GILD ) says its Marketing Authorization Application for sofosbuvir, for the treatment of chronic hepatitis C virus, has been fully validated by the European Medicines Agency and is ...
Gilead Sciences ( GILD ) says its Marketing Authorization Application for sofosbuvir, for the treatment of chronic hepatitis C virus, has been fully validated by the European Medicines Agency and is now under assessment. Post your comment!
-
10 High-Conviction Purchases by Our Ultimate Stock Pickers
… Fair Value Fair Value Uncertainty Market Cap ($ Mil.) # Funds Buying Apple AAPL 4 Narrow 433.26 0.72 High 405,446 4 Gilead GILD 4 Narrow 56.30 0.79 Medium 87,971 3 Apache APA 4 Narrow 81.30 0.74 Medium 32,019 2 Abbott Labs ABT 2 Narrow 36 …
-
Gilead Sciences' Management Presents at the 2013 UBS Global Healthcare Conference (Transcript)
… 09:30 End Time: 09:51 Gilead Sciences , Inc . ( GILD ) Company Conference Presentation ..... privileged to introduce here Gilead Sciences which is the market leader ..... com/article/1447611- gilead - sciences -management-presents …
-
Here's Why Amgen Shares Are Worth $117 To $126 Today
… about 22% YTD) and has greatly lagged its large-cap biotech peers. For instance, this year so far shares of Gilead Sciences ( GILD ) (up 50% YTD), Celgene ( CELG ) (up 57% YTD), Biogen Idec ( BIIB ) (up 55% YTD), and Regeneron Pharmaceuticals …
-
Gilead Sciences ([[ GILD ]] +2.4%) finishes higher today after UBS raised its price target to $67 from $63 and reiterated its Buy rating. Analyst Matthew Roden sees ongoing strength for its HIV ...
Gilead Sciences ( GILD +2.4% ) finishes higher today after UBS raised its price target to $67 from $63 and reiterated its Buy rating. Analyst Matthew …
-
Cramer's Lightning Round - I've Had It With Magnum Hunter (5/16/13)
By SA Editor Miriam Metzinger : Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday May 16. Bullish Calls: Gilead ( GILD ): "I think it is terrific. You buy 25 tomorrow and hope it comes in." Federal Realty Complete Story »
-
Infinity Pharmaceuticals ([[INFI]] -20.5%) gets slammed by cautious comments out of JPMorgan today, saying that investors are "growing increasingly skittish" ahead of [[INFI]]'s pending presentation ...
… 145, its experimental leukemia drug, and while the investment bank predicts "a good showing," it may not be enough to outshine Gilead ( GILD -2.3% ), Pharmacyclics ( PCYC -2.5% ) or Roche ( RHHBY.OB -0.6% ). 1 comment!
-
Experimental Gilead drug effective in early-stage leukemia trial
May 15 (Reuters) - An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world's biggest seller of HIV medications.
-
New Morningstar Analyst Report - Celgene
… we think Vidaza sales in Europe should remain protected until 2018. Given Revlimid's 95% gross margin and Gilead Sciences ' GILD success with its small-molecule drugs, we see adjusted operating margins approaching 50% in Celgene's future …
-
Gilead's Hepatitis C Drug Sofosbuvir Offers Upside
… individual biotech stocks, including Gilead Sciences ( GILD ), the company best known for its HIV drugs. Gilead 's shares have jumped 43% this year ..... hepatitis C drug sofosbuvir -- a drug Gilead obtained in its $11.2 billion acquisition …